Topical pimecrolimus 1% cream in the treatment of seborrheic dermatitis.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  ˜The œJournal of clinical and aesthetic dermatology

• Publication date

  2013-02-01

• Fields of study

  Medicine

• Identifiers
  PMID 23441238PMCID PMC3579486
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long Term Treatment Concepts and Proactive Therapy for Atopic Eczema

  2012cited by this paper
• Adult seborrheic dermatitis: a status report on practical topical management.

  2011influential reference
• An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face.

  2009cited by this paper
• Role of Topical Calcineurin Inhibitors in the Treatment of Seborrheic Dermatitis

  2009cited by this paper
• Sustained Efficacy and Safety of Pimecrolimus Cream 1% when Used Long‐term (up to 26 Weeks) to Treat Children with Atopic Dermatitis

  2008cited by this paper
• An open‐label efficacy pilot study with pimecrolimus cream 1% in adults with facial seborrhoeic dermatitis infected with HIV

  2007influential reference
• Cancer Concerns with Topical Immunomodulators in Atopic Dermatitis

  2007cited by this paper
• Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis.

  2007cited by this paper
• The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force.

  2006cited by this paper
• Pimecrolimus cream 1% is effective in seborrhoeic dermatitis refractory to treatment with topical corticosteroids.

  2006cited by this paper
• Low Systemic Absorption and Good Tolerability of Pimecrolimus, Administered as 1% Cream (Elidel®) in Infants with Atopic Dermatitis – A Multicenter, 3‐Week, Open‐Label Study

  2005cited by this paper
• Immunomodulation and Safety of Topical Calcineurin Inhibitors for the Treatment of Atopic Dermatitis

  2005cited by this paper
• Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment.

  2004cited by this paper
• Pimecrolimus – an anti‐inflammatory drug targeting the skin

  2004cited by this paper
• Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus.

  2004cited by this paper
• Pimecrolimus cream 1% vs. betamethasone 17‐valerate 0·1% cream in the treatment of seborrhoeic dermatitis. A randomized open‐label clinical trial

  2004influential reference
• Pimecrolimus cream 1% can be an effective treatment for seborrheic dermatitis of the face and trunk.

  2004cited by this paper
• Alcohol-induced application site erythema after topical immunomodulator use and its inhibition by aspirin.

  2004cited by this paper
• Topical pimecrolimus in the treatment of seborrheic dermatitis.

  2003cited by this paper
• PIMECROLIMUS: A REVIEW OF PRE‐CLINICAL AND CLINICAL DATA

  2003cited by this paper
• Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis.

  2003cited by this paper
• An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis.

  2003cited by this paper
• Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients

  2003cited by this paper
• Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Adults: A Six-Month Study

  2002cited by this paper
• A Double-Blind Placebo-Controlled Study of Ketoconazole + Desonide Gel Combination in the Treatment of Facial Seborrheic Dermatitis

  2002cited by this paper
• Low Systemic Exposure after Repeated Topical Application of Pimecrolimus (Elidel®, SD Z ASM 981) in Patients with Atopic Dermatitis

  2002cited by this paper
• Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.

  2002cited by this paper
• First experience of topical SDZ ASM 981 in children with atopic dermatitis

  2001cited by this paper
• Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry

  2001cited by this paper
• The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double‐blind controlled study

  2001influential reference
• Management of Seborrheic Dermatitis and Pityriasis Versicolor

  2000cited by this paper
• A novel anti‐inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology

  1999cited by this paper
• Differentiation of Malassezia species: selectivity of Cremophor EL, castor oil and ricinoleic acid for M. furfur

  1997cited by this paper
• Dermatophytes contain a novel lipid-like leukocyte activator.

  1996cited by this paper
• Effects of Pityrosporum ovale on proliferation, immunoglobulin (IgA, G, M) synthesis and cytokine (IL-2, IL-10, IFNγ) production of peripheral blood mononuclear cells from patients with seborrhoeic dermatitis

  1996cited by this paper

• A clinicodemographic study and life quality Assessment in seborrheic dermatitis at a tertiary care centre in South India

  2025cites this paper
• Effect of Pimecrolimus on apoptotic pathways in H2O2-treated neuron like differentiated-SH-SY5Y cells: a molecular docking and mechanistic study.

  2025cites this paper
• Ocular Manifestations in Seborrheic Dermatitis Epidemiology, Clinical Features, and Management: A Comprehensive Review

  2024cites this paper
• Eyebrow and Eyelash Alopecia: A Clinical Review

  2022cites this paper
• Forced Degradation Studies Of Pimecrolimus As Per ICH Guidelines

  2022cites this paper
• Seborrheic dermatitis and its relationship with Malassezia spp

  2020cites this paper
• Treatment of seborrheic dermatitis: a comprehensive review

  2019cites this paper
• High Staphylococcus epidermidis Colonization and Impaired Permeability Barrier in Facial Seborrheic Dermatitis

  2017cites this paper
• Ekzemerkrankungen in der Adoleszenz

  2016cites this paper
• Estudio comparativo de dos esquemas de tratamiento para dermatitis seborreica capitis con champú de ciclopiroxolamina/piritionato de zinc/keluamida (cpo/pz/k) Comparative Study of Two Treatment's Schemes for Seborrheic Dermatitis with Shampoo of Ciclopiroxolamine/Zinc Pyrithione/Keluamide (cpo/pz/k)

  2015cites this paper
• Pimecrolimus, a topical calcineurin inhibitor used in the treatment of atopic eczema

  2013cites this paper